Phreesia Inc (PHR) Stock Forecast & Price Target

Phreesia is well positioned because its embedded SaaS platform sits inside provider workflows, giving it durable switching costs, broad reach across more than 4,400 healthcare providers, and monetization opportunities across patient intake, payments, and network solutions. In 2Q27, revenue rose 10% to $129.5 million, adjusted EBITDA reached $32.9 million, and margin expanded to 25.4% as restructuring and disciplined expense control drove operating leverage, while cash of $74.6 million exceeded long-term debt of $61.2 million. Its positive outlook is further supported by 6.2% provider-client growth, strong payment processing growth, early AccessOne traction, and a large opportunity to deepen monetization without relying on aggressive price increases.

Phreesia is facing a weaker fundamental setup as management held FY27 revenue guidance at $515M for a second straight quarter, implying only 7% year-over-year growth and less than 1% organic growth despite some progress in network solutions and Provider Connect. The outlook is further pressured by a cut to full-year subscription revenue growth from +4% to (4%), a lower FY28 top-line estimate of $540M, and execution risk around AccessOne, which is being pushed to FY28 and could limit free cash flow and debt repayment capacity. Although FY27 adjusted EBITDA is still guided at $125M-$135M, rising hiring and AI costs, plus competitive threats from larger vendors and dependence on payment-processing volumes, make the stock’s risk-reward unattractive.